ATE548048T1 - Oncomodulin zur behandlung von neurologishen erkrankungen - Google Patents

Oncomodulin zur behandlung von neurologishen erkrankungen

Info

Publication number
ATE548048T1
ATE548048T1 AT01946052T AT01946052T ATE548048T1 AT E548048 T1 ATE548048 T1 AT E548048T1 AT 01946052 T AT01946052 T AT 01946052T AT 01946052 T AT01946052 T AT 01946052T AT E548048 T1 ATE548048 T1 AT E548048T1
Authority
AT
Austria
Prior art keywords
oncomodulin
treatment
neurological diseases
subject
regeneration
Prior art date
Application number
AT01946052T
Other languages
English (en)
Inventor
Larry Benowitz
Original Assignee
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center filed Critical Childrens Medical Center
Application granted granted Critical
Publication of ATE548048T1 publication Critical patent/ATE548048T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1738—Calcium binding proteins, e.g. calmodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
AT01946052T 2000-06-01 2001-06-01 Oncomodulin zur behandlung von neurologishen erkrankungen ATE548048T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20877800P 2000-06-01 2000-06-01
PCT/US2001/017895 WO2001091783A2 (en) 2000-06-01 2001-06-01 Methods and compositions for producing a neurosalutary effect in a subject

Publications (1)

Publication Number Publication Date
ATE548048T1 true ATE548048T1 (de) 2012-03-15

Family

ID=22776024

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01946052T ATE548048T1 (de) 2000-06-01 2001-06-01 Oncomodulin zur behandlung von neurologishen erkrankungen

Country Status (7)

Country Link
US (2) US20020119923A1 (de)
EP (1) EP1289540B1 (de)
JP (1) JP2003534385A (de)
AT (1) ATE548048T1 (de)
AU (2) AU2001268147B2 (de)
CA (1) CA2411666A1 (de)
WO (1) WO2001091783A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002333510A1 (en) * 2001-08-29 2003-03-18 Eucro European Contract Research Gmbh And Co. Kg Use of beta-adrenoceptor agonists for the treatment of neurodegenerative diseases
EP1542702A4 (de) * 2002-09-27 2008-08-27 Childrens Medical Center Verfahren und zusammensetzungen zur behandlung von neurologischen störungen
AU2003300012A1 (en) * 2002-12-30 2004-07-29 Indiana University Research & Technology Corporation Method of treatment for central nervous system injury
FR2851247B1 (fr) * 2003-02-19 2007-06-29 Exonhit Therapeutics Sa Methodes et compositions pour le traitement de pathologies degeneratives oculaires
WO2007022524A2 (en) * 2005-08-19 2007-02-22 Neuronetrix, Inc. Controller for neuromuscular testing
WO2007133749A2 (en) * 2006-05-12 2007-11-22 Children's Medical Center Corporation Methods and compositions for treating and preventing peripheral nerve damage
US20080140008A1 (en) * 2006-12-06 2008-06-12 Medtronic, Inc. Intrathecal catheter
EP2282738A4 (de) 2008-06-06 2011-12-21 Childrens Medical Center Förderung der neutritregeneration im erwachsenen zns durch steuerung der proteintranslation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19525416A1 (de) * 1995-07-12 1997-01-16 Bioph Biotech Entw Pharm Gmbh Verwendung von MP52 zur Behandlung und Prävention von Erkrankungen des Nervensystems
FR2720069A1 (fr) * 1994-05-19 1995-11-24 Inst Nat Sante Rech Med Dérivés de facteurs de croissance et d'hormones de la superfamille des TGFB, procédé pour leur obtention et leurs applications biologiques.
US6214796B1 (en) * 1996-03-22 2001-04-10 The General Hospital Corporation Administration of polypeptide growth factors following central nervous system ischemia or trauma
ES2252974T3 (es) * 1998-09-03 2006-05-16 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrieb Von Pharmaka Mbh Utilizacion de inhibidores de tgf-beta para tratar los transtornos cerebrales.

Also Published As

Publication number Publication date
WO2001091783A3 (en) 2002-07-11
JP2003534385A (ja) 2003-11-18
WO2001091783A2 (en) 2001-12-06
EP1289540B1 (de) 2012-03-07
AU6814701A (en) 2001-12-11
CA2411666A1 (en) 2001-12-06
US20050059594A1 (en) 2005-03-17
US20020119923A1 (en) 2002-08-29
EP1289540A2 (de) 2003-03-12
AU2001268147B2 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
ATE202940T1 (de) Mittel und methoden zur behandlung von plaque- krankheiten
ATE213164T1 (de) Verwendung von nona- und dekapeptiden zur herstellung eines arzneimittels zur bekämpfung von aids
YU46097A (sh) Nova klasa estara i njihove farmaceutske smeše
WO2004006858A3 (en) Compounds, compositions, and methods employing same
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
DE60036169D1 (de) Methoden zur Behandlung der Hautpigmentierung
ATE417602T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
NO20012774D0 (no) Preparat og metode hvor det gjöres bruk av eteriske planteoljer
DK1525177T3 (da) Substituerede 1,3-diphenylprop-2-en-1-on-derivater, fremstilling og anvendelse deraf
MXPA03005340A (es) Nuevas composiciones de medicamentos a base de anticolinergicos y ciclesonida.
DK1654253T3 (da) Substituerede 3-pyrrolidinindolderivater
IL171974A0 (en) Tetrahydrocarbazole derivatives and their pharmaceutical use
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
RS50148B (sr) Upotreba docetaksela za lečenje hepatoćelijskog karcinoma
BG105275A (en) Tan-1057 derivatives
ATE548048T1 (de) Oncomodulin zur behandlung von neurologishen erkrankungen
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
TR200200278T2 (tr) Kalsilitik bileşimler
DE60124093D1 (de) S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen.